Search results for "Topi"

showing 10 items of 3172 documents

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

2014

Abstract Background Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Field of study PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms “Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) “; papers considered relevant for the aim of this review were selected. Findings/results The phase I trials have determine…

0301 basic medicineOncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerTrastuzumabInternal medicineHumansMedicineMaytansineProgression-free survivalNeoplasm Metastasisskin and connective tissue diseasesTaxanebusiness.industryCancerHematologyTrastuzumabmedicine.diseaseMetastatic breast cancerClinical trial030104 developmental biologyClinical Trials Phase III as TopicOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisDisease ProgressionFemaleNeoplasm Recurrence Localbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

2019

The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating…

0301 basic medicineOrganoplatinum CompoundsImmune checkpoint inhibitorsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorLeucovorinReviewLymphocyte ActivationchemotherapyimmunomodulationB7-H1 AntigenMice0302 clinical medicineAntineoplastic Agents ImmunologicalcheckpointT-Lymphocyte SubsetsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentImmunology and AllergyCTLA-4 AntigenMolecular Targeted TherapyClinical Trials as TopicLymphokinesDrug Synergism3. Good healthNeoplasm ProteinsFluorouracillcsh:Immunologic diseases. AllergyImmunologyCancer therapyT cells03 medical and health sciencesImmune systemmedicineAnimalsHumanscancerIn patientChemotherapybusiness.industryCancermedicine.diseaseIpilimumabBlockade030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer researchlcsh:RC581-607business030215 immunologyFrontiers in immunology
researchProduct

IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells

2016

Background Cutaneous exposure to food allergens predisposes to food allergy, which is commonly associated with atopic dermatitis (AD). Levels of the epithelial cytokine IL-33 are increased in skin lesions and serum of patients with AD. Mast cells (MCs) play a critical role in food-induced anaphylaxis and express the IL-33 receptor ST2. The role of IL-33 in patients with MC-dependent food anaphylaxis is unknown. Objective We sought to determine the role and mechanism of action of IL-33 in patients with food-induced anaphylaxis in a model of IgE-dependent food anaphylaxis elicited by oral challenge of epicutaneously sensitized mice. Methods Wild-type, ST2-deficient, and MC-deficient Kit W-sh/…

0301 basic medicineOvalbuminImmunologyMice TransgenicAdministration CutaneousImmunoglobulin Emedicine.disease_causeArticleDermatitis Atopic03 medical and health sciences0302 clinical medicineAllergenFood allergymedicineAnimalsHumansImmunology and AllergyMast CellsRNA MessengerAnaphylaxisSkinMice Inbred BALB Cbiologybusiness.industryDegranulationAllergensImmunoglobulin EInterleukin-33medicine.diseaseMast cellInterleukin 33Ovalbumin030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinFemalebusinessFood HypersensitivityAnaphylaxis030215 immunologyJournal of Allergy and Clinical Immunology
researchProduct

miR-9 and miR-200 regulate PDGFRβ-mediated endothelial differentiation of tumor cells in triple-negative breast cancer

2016

Abstract Organization of cancer cells into endothelial-like cell-lined structures to support neovascularization and to fuel solid tumors is a hallmark of progression and poor outcome. In triple-negative breast cancer (TNBC), PDGFRβ has been identified as a key player of this process and is considered a promising target for breast cancer therapy. Thus, we aimed at investigating the role of miRNAs as a therapeutic approach to inhibit PDGFRβ-mediated vasculogenic properties of TNBC, focusing on miR-9 and miR-200. In MDA-MB-231 and MDA-MB-157 TNBC cell lines, miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro. Induction of endogenous miR-9…

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchCellular differentiationBlotting WesternFluorescent Antibody TechniqueTriple Negative Breast NeoplasmsMice SCIDBiologySettore MED/08 - Anatomia PatologicaPolymerase Chain ReactionNeovascularizationReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesMice0302 clinical medicinemicroRNAmedicineAnimalsHumansTriple-negative breast cancerIn Situ HybridizationRegulation of gene expressionNeovascularization PathologicCancerEndothelial CellsCell Differentiationmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticMicroRNAs030104 developmental biologyOncologyOncology; Cancer Research030220 oncology & carcinogenesisGene Knockdown TechniquesCancer cellCancer researchHeterograftsEctopic expressionFemalemedicine.symptom
researchProduct

Prenatal Ambient Air Pollution, Placental Mitochondrial DNA Content, and Birth Weight in the INMA (Spain) and ENVIRONAGE (Belgium) Birth Cohorts

2016

The research leading to these results was funded by the Spanish Ministry of Health (FIS-PI11/00610, FIS-PI041436, FIS-PI081151, FIS-PI042018, and FIS-PI09/02311), the European Union (EU) (FP7-ENV-2011 cod 282957 and HEALTH.2010.2.4.5-1), the Instituto de Salud Carlos III (Red INMA G03/176, CB06/02/0041, FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 09/02647, 11/01007, 11/02591, CP11/00178, FIS-PI06/0867, and FIS-PS09/00090), the Conselleria de Sanitat Generalitat Valenciana, the Generalitat de Catalunya-CIRIT (1999SGR 00241), the Obre Social Cajastur, the Universidad de Oviedo, the Department of Health of the Basque Government (2005111093 and 2009111069),…

0301 basic medicinePediatrics:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Birth Weight [Medical Subject Headings]:Phenomena and Processes::Physiological Phenomena::Physiological Processes::Growth and Development::Morphogenesis::Embryonic and Fetal Development::Fetal Development [Medical Subject Headings]Health Toxicology and MutagenesisPlacentaEspañaPhysiology:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Growth Disorders::Fetal Growth Retardation [Medical Subject Headings]ADN mitocondrial010501 environmental sciencesMitochondrion01 natural sciencesFetal DevelopmentBélgicaPregnancyBirth Weightskin and connective tissue diseasesPeso al nacerNews | Science SelectionsMitocondrias:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Reproduction::Pregnancy [Medical Subject Headings]:Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Mitochondria [Medical Subject Headings]2. Zero hunger:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]Air PollutantsAmbient air pollutionAire -- ContaminacióFemenino3. Good healthmedicine.anatomical_structureMaternal ExposureFemaleBirth cohort:Health Care::Environment and Public Health::Public Health::Environmental Pollution::Air Pollution [Medical Subject Headings]Mitochondrial DNAmedicine.medical_specialtyModelos LinealesEmbarazoBirth weightInfants -- DesenvolupamentBiology:Chemicals and Drugs::Inorganic Chemicals::Gases::Nitrogen Oxides::Nitrogen Dioxide [Medical Subject Headings]DNA Mitochondrial:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes Mitochondrial [Medical Subject Headings]03 medical and health sciencesAir pollutantsPlacentaAir PollutionmedicineHumans:Geographicals::Geographic Locations::Europe::Belgium [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Linear Models [Medical Subject Headings]Contaminación del aire0105 earth and related environmental sciencesRetardo del crecimiento fetal:Chemicals and Drugs::Nucleic Acids Nucleotides and Nucleosides::Nucleic Acids::DNA::DNA Circular::DNA Mitochondrial [Medical Subject Headings]Genes mitocondrialesPregnancyPublic Health Environmental and Occupational HealthDesarrollo fetalmedicine.disease:Anatomy::Embryonic Structures::Placenta [Medical Subject Headings]030104 developmental biology:Check Tags::Female [Medical Subject Headings]13. Climate actionSpainsense organsDióxido de nitrógeno
researchProduct

Changes in fruit and vegetable consumption habits from pre-pregnancy to early pregnancy among Norwegian women

2017

Background: A healthy diet is important for pregnancy outcome and the current and future health of woman and child. The aims of the study were to explore the changes from pre-pregnancy to early pregnancy in consumption of fruits and vegetables (FV), and to describe associations with maternal educational level, body mass index (BMI) and age. Methods: Healthy nulliparous women were included in the Norwegian Fit for Delivery (NFFD) trial from September 2009 to February 2013, recruited from eight antenatal clinics in southern Norway. At inclusion, in median gestational week 15 (range 9–20), 575 participants answered a food frequency questionnaire (FFQ) where they reported consumption of FV, bot…

0301 basic medicinePediatricsCross-sectional studyHabitsRisk FactorsPregnancySurveys and QuestionnairesVegetablesObstetrics and GynaecologySingle-Blind MethodYoung adultNorwayIncidence (epidemiology)IncidencePregnancy OutcomePreconceptionObstetrics and GynecologyNutrition SurveysFruit and Vegetable JuiceslanguageGestationFemaleResearch ArticleAdultmedicine.medical_specialtyReproductive medicineNorwegianlcsh:Gynecology and obstetricsFruits03 medical and health sciencesYoung AdultPatient Education as TopicmedicineHumanslcsh:RG1-991Retrospective StudiesPregnancy030109 nutrition & dieteticsbusiness.industryFeeding BehaviorMaternal Nutritional Physiological Phenomenamedicine.diseaselanguage.human_languageDietPregnancy ComplicationsCross-Sectional StudiesFruitWomen's HealthbusinessBody mass indexDemographyFollow-Up StudiesBMC Pregnancy and Childbirth
researchProduct

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

2019

Abstract Objectives In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates. Methods A ‘meta-model’ with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0–24 of 400 mg·h/L at steady-state in at least 80% of neonates. Results A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if &lt…

0301 basic medicinePediatricsvancomycininfusion procedures0302 clinical medicinenewbornMedicinePharmacology (medical)Randomized Controlled Trials as Topiceducation.field_of_studyMaintenance doseAnti-Bacterial Agents3. Good healthInfectious Diseasesdrug maintenance doseResearch DesignArea Under CurveData Interpretation Statisticalcreatinine testsVancomycinMonte Carlo Methodmedicine.drugMicrobiology (medical)medicine.medical_specialty030106 microbiologyPopulationGestational AgeMicrobial Sensitivity TestsLoading doseRS03 medical and health sciencesPharmacokineticsdrug loading dose030225 pediatricsHumanssteady stateeducationPharmacologyDose-Response Relationship Drugbusiness.industryBody WeightInfant NewbornPostmenstrual AgeinfantNONMEMRegimen[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieregimen[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessserum
researchProduct

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.

2016

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this …

0301 basic medicinePeroxisome Proliferator-Activated Receptormedicine.medical_specialtyPeroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptor030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationPPAR agonist03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsCardiovascular DiseaseInternal medicineDiabetes mellitusDrug DiscoverymedicineAnimalsHumansDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationClinical Trials as TopicHypolipidemic Agentmedicine.diagnostic_testAnimalbusiness.industryRisk FactorAtherogenic dyslipidemiaCardiovascular riskmedicine.diseaseAtherosclerosisObesityThiazoles030104 developmental biologyEndocrinologyDyslipidemiachemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessHumanLipoproteinCurrent pharmaceutical design
researchProduct

Extracellular Vesicles: Goodies for the Brain?

2015

0301 basic medicinePharmacologyHot TopicsBrainBiological TransportBiologyExtracellular vesicles03 medical and health sciencesPsychiatry and Mental healthExtracellular Vesicles030104 developmental biology0302 clinical medicineAnimalsHomeostasisHumansNeuroscience030217 neurology & neurosurgeryHomeostasis
researchProduct